Clinical Metabolomics and Glaucoma

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2018

Autores

Barbosa Breda, J (Autor) FMUP; Himmelreich, U (Autor) Outra; Ghesquiere, B (Autor) Outra; Rocha-Sousa A (Autor) FMUP; Stalmans, I (Autor) Outra

Revista

Título: Ophthalmic Research

Vol. 59

Páginas: 1-6

ISSN: 0030-3747

Editora: Karger

Indexação

ISI Web of Knowledge - 30 Citações

Scopus - 36 Citações

Outras Informações

ID Authenticus: P-00N-MEH

DOI: 10.1159/000479158

Abstract (EN): Glaucoma is one of the leading causes of irreversible blindness worldwide. However, there are no biomarkers that accurately help clinicians perform an early diagnosis or detect patients with a high risk of progression. Metabolomics is the study of all metabolites in an organism, and it has the potential to provide a biomarker. This review summarizes the findings of metabolomics in glaucoma patients and explains why this field is promising for new research. We identified published studies that focused on metabolomics and ophthalmology. After providing an overview of metabolomics in ophthalmology, we focused on human glaucoma studies. Five studies have been conducted in glaucoma patients and all compared patients to healthy controls. Using mass spectrometry, significant differences were found in blood plasma in the metabolic pathways that involve palmitoylcarnitine, sphingolipids, vitamin D-related compounds, and steroid precursors. For nuclear magnetic resonance spectroscopy, a high glutamine-glutamate/creatine ratio was found in the vitreous and lateral geniculate body; no differences were detected in the optic radiations, and a lower N-acetylaspartate/ choline ratio was observed in the geniculocalcarine and striate areas. Metabolomics can move glaucoma care towards a personalized approach and provide new knowledge concerning the pathophysiology of glaucoma, which can lead to new therapeutic options. (C) 2017 S. Karger AG, Basel

Idioma: Inglês

Tipo (Avaliação Docente): Divulgação

Nº de páginas: 6